Something about the newer, more potent formulations, or perhaps the degree of weight loss they produce, drives the risk higher
Youll inject once weekly into your abdomen, thigh, or upper arm
Zhang C, Syed TW, Liu R, Yu J
The company's marketing materials suggest the product may help users "feel lighter" and experience reduced "tension" and "heaviness." Individual testimonials reflect personal experiences and do not constitute clinical evidence or predict typical results
EMA decision anticipated June 2026 Why It Matters: Adherence remains a key barrier in LDL-C management with statins and injectables LEROCHOL introduces meaningful differentiation versus Repatha and Praluent, particularly on storage and usability Expands access to potent lipid lowering for high-risk cardiovascular patients Key Takeaway: LEROCHOL strengthens the PCSK9 landscape with a long-acting, patient-friendly biologicraising the bar on convenience while intensifying competition in cardiovascular risk reduction
Once desired tan is achieved, reduce to 23 sprays per week for maintenance